Out in @JCI_insight with @drshawnkwatra and coauthors: we characterized the somatic mutational landscape of prurigo nodularis with evidence of hyperactive Notch signaling in lesional skin, links to fibrosis, neuroinflammation, and racial differences!
https://t.co/rPxsMDKTbb
Extremely proud of the team, especially @GHWANPhD, @khattabsaray, and @wxchen953 for our @TheLancetOncol study on multi-organ toxicities from checkpoint blockade, providing a roadmap for prognosticating outcomes via the lens of immunotherapy toxicities: https://t.co/Vy7pHIftgo
Genetic variation is relatively poorly studied in the Middle East, particularly where endogamy and consanguinity are more common. Among 6K WGS in Qatar, 2 in 3 (!) was a carrier for a pathogenic mutation for an autosomal recessive condition. https://t.co/dIsv8O0uRG @GenomeMedicine
Very excited to share our Delphi consensus guidelines to diagnosing dermatologic immunotherapy toxicites. Incredible team effort from more than 30 experts, including @DrStevenTChen@kreynoldsMD, @DrJNaidoo, and Nicole LeBoeuf.
Radiation recall is a fascinating clincal phenomenon that I learned about during clinic when I first visited @WashUDerm. Here in @JAMADerm we report on a case of radiation recall with two BTK-inhibitors. Many many thanks to Dr. Anadkat and Dr. Ferree. #MedTwitter#dermtwitter
Our study led by @buutrg leverages the full corpus of polygenic risk scores to construct the best performing PRS for a target population https://t.co/xfjdBeIBYO @CellGenomics
Check out 🧵👇 by @buutrg
Overwhelmed with love and kindness! Thank you all for the replies.
I could not have asked for a better research year experience with @EugeneSemenovMD and @drshawnkwatra. Thank you for the infinite guidance, support, and for opening so many doors for me!
Today, I matched into dermatology at my top choice and dream program @WashUDerm 🥹
Alhamdullah
I am beyond grateful to my mentors, my family, and everyone who supported me or just believed in me along this journey. Cannot wait to get to work!
#Match2024#dermtwitter
Last year, we did not match.
This year, my wife matched in dermatology at UC Irvine, and I matched in ophthalmology at UCLA. During the reapplication process, we received the greatest gift from God, our son, who has brought us immense joy. Thank you everyone! #Match2024
Excited to share our @JAMADerm viewpoint https://t.co/gr3NepEeWB examining immunotherapy in localized melanoma. Big congrats to @HannahRashdan in my lab for leading the piece, which was also a hot topic @ the most recent @MelanomaReAlli meeting! Thx to @AdeAdamson for his collab.
🌟 Breaking News in Healthcare! @GlassHealth just announced #Consult, an AI marvel 🤖🩺.
It's not just a chatbot, it's a revolution in clinical decision-making, backed by peer-reviewed wisdom!
Every clinician's new best friend, providing instant, evidence-based guidance.
Very excited by our results @Nature showing that IL4R signaling is strongly enriched in myeloid cells that infiltrate mice and lung cancer lesions https://t.co/Nnjc7ue96y
So grateful for your mentorship and support @drshawnkwatra
Incredibly honored to share our creative analysis of somatic mutations in prurigo nodularis. Check out the preprint and overview below! 😊
#MedTwitter#dermtwitter
New study alert 🚨📜
In this original investigation led by the talented @rajehTea, we perform a first-ever comprehensive somatic mutational analysis of #prurigo nodularis, challenging our understanding of the dz.
Paper: https://t.co/R82lnI9iWD
🧵 a few takeaways below 1/8
‣ 25% of pts w melanomas >1-mm did not undergo SLNB
‣ Most of these cases were due to age/comorbidities
‣ Uninsured status and lentigo maligna histology were associated with SLNB non-completion
‣ SLNB non-completion was associated w worse overall and recurrence-free survival
Published in @JAADjournals! https://t.co/hG2uCttoKX 📢
The role of SLNB in #melanoma remains controversial. We examined the utilization of SLNB and its impact on survival. Main findings below👇
Huge thanks to my inspiring mentor @EugeneSemenovMD and co-authors! #dermtwitter
Are you better off being taken care of by an MD or DO?
@jbcarmody & I had the honor to discuss the recent @AnnalsofIM paper that found no differences in 30-day mortality,�� readmissions, LOS, or health care costs between MD and DO's...
https://t.co/aCoiBDfXMi
A quick 🧵...